Rosenberg S H, Woods K W, Sham H L, Kleinert H D, Martin D L, Stein H, Cohen J, Egan D A, Bopp B, Merits I
Abbott Laboratories, Cardiovascular Research Division, Abbott Park, Illinois 60064.
J Med Chem. 1990 Jul;33(7):1962-9. doi: 10.1021/jm00169a024.
Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.